Urmăriți
Philip Newsome
Titlu
Citat de
Citat de
Anul
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ...
Journal of hepatology 73 (1), 202-209, 2020
27852020
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ...
Gastroenterology 158 (7), 1999-2014. e1, 2020
23372020
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
MJ Armstrong, P Gaunt, GP Aithal, D Barton, D Hull, R Parker, ...
The Lancet 387 (10019), 679-690, 2016
18132016
Pathogenesis of non-alcoholic fatty liver disease
JK Dowman, JW Tomlinson, PN Newsome
QJM: An International Journal of Medicine 103 (2), 71-83, 2010
10562010
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
10012019
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
P Ramachandran, R Dobie, JR Wilson-Kanamori, EF Dora, ...
Nature 575 (7783), 512-518, 2019
9832019
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
PN Newsome, K Buchholtz, K Cusi, M Linder, T Okanoue, V Ratziu, ...
New England Journal of Medicine 384 (12), 1113-1124, 2021
9562021
Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease
PJ Eddowes, M Sasso, M Allison, E Tsochatzis, QM Anstee, D Sheridan, ...
Gastroenterology 156 (6), 1717-1730, 2019
9022019
A multi-society Delphi consensus statement on new fatty liver disease nomenclature
ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ...
Annals of Hepatology, 101133, 2023
6952023
Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol …
R Williams, R Aspinall, M Bellis, G Camps-Walsh, M Cramp, A Dhawan, ...
The Lancet 384 (9958), 1953-1997, 2014
6762014
Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis
RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ...
Gastroenterology 158 (6), 1611-1625. e12, 2020
6662020
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
T Boettler, PN Newsome, MU Mondelli, M Maticic, E Cordero, M Cornberg, ...
JHEP reports 2 (3), 100113, 2020
5292020
Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling
DC Hay, J Fletcher, C Payne, JD Terrace, RCJ Gallagher, J Snoeys, ...
Proceedings of the National Academy of Sciences 105 (34), 12301-12306, 2008
5282008
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation …
PN Newsome, M Sasso, JJ Deeks, A Paredes, J Boursier, WK Chan, ...
The lancet Gastroenterology & hepatology 5 (4), 362-373, 2020
4982020
Guidelines on the management of abnormal liver blood tests
PN Newsome, R Cramb, SM Davison, JF Dillon, M Foulerton, EM Godfrey, ...
Gut 67 (1), 6-19, 2018
4522018
Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
JK Dowman, JW Tomlinson, PN Newsome
Alimentary pharmacology & therapeutics 33 (5), 525-540, 2011
4512011
Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells
SFH de Witte, F Luk, JM Sierra Parraga, M Gargesha, A Merino, ...
stem cells 36 (4), 602-615, 2018
4472018
A concise review of non-alcoholic fatty liver disease
NN Than, PN Newsome
Atherosclerosis 239 (1), 192-202, 2015
4222015
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
MJ Armstrong, D Hull, K Guo, D Barton, JM Hazlehurst, LL Gathercole, ...
Journal of hepatology 64 (2), 399-408, 2016
4162016
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
MJ Armstrong, DD Houlihan, L Bentham, JC Shaw, R Cramb, S Olliff, ...
Journal of hepatology 56 (1), 234-240, 2012
4062012
Sistemul nu poate realiza operația în acest moment. Încercați din nou mai târziu.
Articole 1–20